Drugs / Mutant-CALR peptides
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05025488 | Apr 2023 → Mar 2027 expected | essential thrombocythemia, myelofibrosis | Marina Kremyanskaya | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mutant-CALR peptides | “ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only).” NCT05025488 ↗ |
| Action | Deplete | “target and eliminate CALR+ malignant cells” NCT05025488 ↗ |
| Modality | Vaccine | “peptide-based vaccine” NCT05025488 ↗ |